A next-generation sequencing (NGS) assay was developed assessing genes that are known to be frequently mutated or deleted in pancreatic cysts (KRAS, GNAS, NRAS, HRAS, BRAF, CTNNB1, TP53, PIK3CA, PTEN and AKT1) in combination with Sanger sequencing of VHL. The gene discussed is TP53; the disease is Pancreatic cysts.